STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #497 by analyst upside · 2026-06-27
SLN
Silence Therapeutics plc
Healthcare · Market Cap $479M · P/E 0x
ANALYST PRICE TARGET
+187.6%
implied upside to consensus target
Current Price $10.14
Consensus Target $29.17
Bull Target $75.0
Bear Target $4.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
1
52-Week Low $4.19
52-Week High $10.63
YTD Return +64.9%
FUNDAMENTALS
Market Cap $479M
P/E Ratio (TTM) N/A
Forward P/E -26.0x
EPS (TTM) $-1.62
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.19
52-Week High $10.63
Current Price $10.14
Bear Target $4.0
Bull Target $75.0
● Now $10.14 ● Target $29.17
TRADING DATA
Avg Volume 353K
YTD Return +64.9%
Analyst Count 6
Consensus Buy
Upside to Target +187.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Silence Therapeutics plc (SLN) is currently trading at $10.14 with a Wall Street consensus price target of $29.17, implying potential upside of 187.6% over the next 12 months. 6 analysts currently cover SLN, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $75.0, while the most cautious has a target of $4.0.

SLN operates in the Healthcare sector with a market capitalisation of $479M. The stock is up 64.9% year-to-date and is currently trading near the upper end of its 52-week range of $4.19 – $10.63.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SLN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-17 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-13 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-09-16 31% win rate (48 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-06-13 31% win rate (48 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-06-13 33% win rate (6 calls)
Goldman Sachs — Reiterated
Sell → Sell 2025-05-09 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2025-05-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
37
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →